维普中文期刊产品整合服务
360篇 您的检索式:作者名="Nott"
    题名 作者 年代 出处 被引量
1HOLMIUM: YAG LASER LITHOTRIPSY FOR UPPER URINARY TRACT CALCULI IN 598 PATIENTS显示文摘MARIO SOFER JAMES D. WATTERSON TIMOTHY A. WOLLIN LINDA NOTT HASSAN RAZVI JOHN D. DENSTEDT 2002The Journal of Urology2002,,1:4
2Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone.Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill 2015World Journal of Gastroenterology2015,21,17:3
3HOLMIUM: YAG LASER LITHOTRIPSY FOR UPPER URINARY TRACT CALCULI IN 598 PATIENTS显示文摘MARIO SOFER JAMES D. WATTERSON TIMOTHY A. WOLLIN LINDA NOTT HASSAN RAZVI JOHN D. DENSTEDT 2002The Journal of Urology2002,,1:2
4Hemolytic activity of new linear surfactin aanalogs in relation to their physico-chemical properties显示文摘Dufour S Deleu M Nott K 2005Biochim Biophys Acta2005,,:1
5Satiation amount, frequency of feeding and gastric emptying rate in Salmo gairdneri显示文摘GROVE D J LOZOIDES L NOTT J 1978Journal of Fish Biology1978,12,4:1
6Hormonal changes and mood in the puerperium显示文摘Nott PM Franklin M Armitage C 1976Br J Psychiatry1976,128,:1
7Salt tolerance in crop plants monitored by chlorophyll fluorescence in vivo显示文摘Smillie R M Nott R 1982Plant physiology1982,70,4:1
8Paleo-climate records in compound-specific 8D values of a lipid biomarker in ombrotrophic peat显示文摘Xie S Nott C J Avsejs L A 2000Organic Geochemistry2000,31,:1
9Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive hmg disease:A clinic trial显示文摘Group NOTT 1980An- nals of Internal Medicine1980,93,:1
10n-Alkane distributions in ombrotrophic mires as indicators of vegetation change related to climatic variations显示文摘Nott C J Xie S Avsejs L A 2000Organic Geochemistry2000,31,:1
11A quantitative analysis of intron effects on mammalian gene expression 显示文摘Nott A Meislin S H Moore M J 2003RNA2003,9,5:1
12PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects显示文摘Patrucco E Notte A Barberis L 2004Cell2004,118,3:1
13Management of massive upper gastrointestinal heamorrhage from multiple sites of peptic ulceration with somctostatin and octreotide -a report of five cases显示文摘Jenkins SA Taylor BA Nott DM 1992Gut1992,33,3:1
14Satiation amount, frequency of feeding and gastric emptying rate in Salmo gairdner 显示文摘Grove D J Loizides L G Nott J 1981Journal of Fish Biology1981,12,:1
15Modern exthaction in the kilo-death range 显示文摘Nott M P Rogers E Pimm D 1994Curr Biol1994,9,:1
16Safety and efficacy of holmium : YAG laser lithotripsy in patients with bleeding diatheses 显示文摘Watterson JD Girvan AR Cook A J Beiko DT Nott L Auge BK 2002Uro12002,168,44:1
17Validation and cross - comparison of MR显示文摘Nott K P Hall L D 2005International Journal of Food Science & Technology2005,40,7:1
18A quantitative analysis of intron effects on mammalian gene expression 显示文摘NOTT A MEISLIN S H MOORE M J 2003RNA2003,9,5:1
19Continuous removal of Cr(VI)from aqueous solution catalysed by palladised biomass of Desulfovibrio vulgaris显示文摘Humphries A Nott K Hall L 2004Biotechnol Lett2004,26,19:1
20How introns influence and enhance gene expression显示文摘LEHIR H NOTT A MOORE M J 2003Trends in the Biochemical Sciences2003,28,:1
返回顶部 每页显示:
共18页 首页 上一页 第1页 下一页 末页 /18 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费